MIRATI THERAPEUTICS INC (MRTX)
US60468T1051 - Common Stock
MIRATI THERAPEUTICS INC
NASDAQ:MRTX (1/22/2024, 7:00:02 PM)
After market: 58.99 +0.29 (+0.49%)58.7
-0.1 (-0.17%)
Company Profile
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Company Info
MIRATI THERAPEUTICS INC
3545 Cray Court
San Diego CALIFORNIA 92121
P: 18583323410
CEO: Charles M. Baum
Employees: 587
Website: https://www.mirati.com/
MRTX News
3 months ago - Seeking AlphaBristol Myers stock cut at Redburn Atlantic (NYSE:BMY)Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.
3 months ago - BloombergBillionaire Joe Lewis Nets 730% Gain on Stock Behind US ChargesBritish billionaire Joe Lewis has sold his stake in a biotechnology firm at the center of the US insider-trading case in which he pleaded guilty this week, cementing an eight-fold gain.
3 months ago - Seeking AlphaBristol Myers Squibb completes Mirati acquisition (NYSE:BMY)Bristol Myers Squibb (BMY) closes its acquisition of Mirati Therapeutics (MRTX) and sees $0.35 per share adj. earnings impact from the deal. Read more here.
3 months ago - Seeking AlphaBristol Myers Squibb closes Mirati acquisition (NYSE:BMY)Bristol Myers Squibb (BMY) closes its acquisition of Mirati Therapeutics (MRTX) and sees $0.35 per share adj. earnings impact from the deal. Read more here.
4 months ago - Seeking AlphaMirati's Krazati gets EU conditional approval for lung cancer (NASDAQ:MRTX)Mirati (MRTX) receives EU conditional approval for its drug Krazati in the treatment of lung cancer with KRAS G12C mutations. Read more here.
4 months ago - Seeking AlphaBristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping
MRTX Twits
Here you can normally see the latest stock twits on MRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
